Phase II, Randomized, Double-Blind ,Placebo-Controlled Study of Hangeshashinto for Prevention of Oral Mucositis in Gastric Cancer Patients Receiving Chemotherapy (HANGESHA-G Study).
- Conditions
- Gastric Cancer
- Registration Number
- JPRN-UMIN000004214
- Lead Sponsor
- PO Epidemiological and Clinical Research Information Network (ECRIN)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 90
Not provided
(1)Patients who had received blood transfusion, blood products, or hematopoietic growth factors such as granulocyte-colony stimulating factor within 7 days prior to registration. (2)Patients who had used traditional Japanese medicines (Kampo) within 2 weeks before registration. (3)History of severe hypersensitivity (allergy) to any medicines. (4)Patients who had received antiphlogistic analgetic, opioid, or steroid. (5)Prior or current therapy for neuropathy or sensory dysfunction. (6)Other active malignancies. (7)Uncontrolled pleural effusion or ascites. (8)A systemic inflammatory condition or serious infection. (9)Brain metastasis. (10)Significant electrocardiographic abnormality. (11)Clinically problematic cardiac disease (congestive heart failure, symptomatic coronary artery disease, uncontrolled arrhythmia, or myocardial infarction within the past 12 months). (12)Severe pulmonary disease (interstitial pneumonia, pulmonary fibrosis, pulmonary emphysema, etc.). (13)Gastrointestinal bleeding that requires medication or transfusion. (14)Diarrhea (watery) or diarrhea that interferes with daily activities for patients with a stoma. (15)Myelosuppresion. (16)Ileus or bowel obstruction. (17)Central nervous system disorders. (18)Dementia. (19)Serious psychological disease. (20)Uncontrolled diabetes mellitus with or without diabetic neuropathy. (21)Serious constipation. (22)Pregnant or lactating women. (23)Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method